Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma

P. Skrabek, S. Assouline, A. Christofides, D. MacDonald, A. Prica, R. Sangha, B. A. Matthews, L. H. Sehn

Abstract


Diffuse large B cell lymphoma (dlbcl) is an aggressive non-Hodgkin lymphoma, accounting for approximately 30% of lymphoma cases in Canada. Although most patients will achieve a cure, up to 40% will experience refractory disease after initial treatment, or relapse after a period of remission. In eligible patients, salvage therapy followed by high-dose therapy and autologous stem-cell transplantation (asct) is the standard of care. However, many patients are transplant-ineligible, and more than half of those undergoing asct will subsequently relapse. For those patients, outcomes are dismal, and novel treatment approaches are a critical unmet need. In this paper, we present available data about emerging treatment approaches in the latter setting and provide a perspective about the potential use of those approaches in Canada


Keywords


Diffuse large B cell lymphoma; DLBCL; non-Hodgkin lymphoma; novel therapies

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.26.5421






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)